文献速递心脑血管急症重症综合管理与镇静镇痛

抗NMDAR脑炎需重症监护患者的癫痫持续状态:随访研究

Status Epilepticus in Patients with Anti-NMDAR Encephalitis Requiring Intensive Care: A Follow-Up Study.
PubMed 文献 · Neurocrit Care · 2021-07-20
一句话结论抗NMDAR脑炎需神经ICU监护者中,出现癫痫持续状态者难治性/超难治性比例高、恢复慢,但多数最终获得良好长期神经结局并在急性期后无发作。

该回顾性研究基于前瞻性登记,分析2014至2019年因抗NMDAR脑炎入住神经ICU的24例患者,按是否出现癫痫持续状态(SE)分组比较临床特征与结局。SE组38.5%(5/13)发生难治性SE、21.3%(3/13)发生超难治性SE;SE组更多以癫痫发作为首发症状(53.8% vs. 9.1%,p=0.033),脑脊液NMDAR抗体强阳性者更多(76.9% vs. 27.3%,p=0.043)。非SE组发病3个月时mRS<2者更多(60.0% vs. 15.4%,p=0.039),但SE组83.3%在9个月时mRS<2,与非SE组相似。SE组41.7%末次发作在发病1个月内,低于非SE组的90%,但所有SE患者急性期后均无发作。

要点

  • 抗NMDAR脑炎需神经ICU监护者中,SE组38.5%(5/13)发生难治性SE、21.3%(3/13)发生超难治性SE。
  • SE组以癫痫发作为首发症状者53.8% vs. 非SE组9.1%(p=0.033),脑脊液NMDAR抗体强阳性者76.9% vs. 27.3%(p=0.043)。
  • 发病3个月时非SE组mRS<2者60.0% vs. SE组15.4%(p=0.039),SE组恢复更慢。
  • SE组83.3%在发病9个月时mRS<2,与非SE组相似;所有SE患者急性期后均无发作。
  • SE组41.7%末次发作在发病1个月内,低于非SE组的90%。

适用人群与场景

  • 2014至2019年因抗NMDAR脑炎入住神经ICU的患者,共24例需重症监护。
  • 按神经ICU期间是否出现癫痫持续状态分为SE组与非SE组。

研究设计与关键结果

  • 研究类型:基于前瞻性登记的回顾性研究;人群:83例抗NMDAR脑炎中24例需重症监护;分组:按是否出现SE分为SE组与非SE组。
  • SE组38.5%(5/13)发生难治性SE,21.3%(3/13)发生超难治性SE。
  • SE组以癫痫发作为首发症状者53.8% vs. 非SE组9.1%(p=0.033)。
  • SE组脑脊液NMDAR抗体强阳性者76.9% vs. 非SE组27.3%(p=0.043)。
  • 发病3个月时非SE组mRS<2者60.0% vs. SE组15.4%(p=0.039)。
  • SE组83.3%在发病9个月时mRS<2,与非SE组相似。
  • SE组41.7%末次发作在发病1个月内,低于非SE组的90%;所有SE患者急性期后均无发作。

证据类型、等级与局限

  • 证据类型:基于前瞻性登记的回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对因抗NMDAR脑炎入住神经ICU的患者,出现SE提示难治性/超难治性SE比例高且恢复更慢,但作者结论认为多数患者最终可获得良好长期神经结局并在急性期后无发作。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: To date, specialized studies focusing on status epilepticus (SE) in anti-N-methyl D-aspartate receptor (anti-NMDAR) encephalitis are limited, and the association between the occurrence of SE and clinical outcome is controversial. This study aims to investigate the differences between patients with critical anti-NMDAR encephalitis with SE and patients who experienced epileptic seizures without SE and to evaluate the long-term disease outcomes of patients with anti-NMDAR encephalitis with SE who were admitted to the neurological intensive care unit (neuro-ICU).

METHODS: In this retrospective study based on a prospective registry, patients with anti-NMDAR encephalitis with neuro-ICU admission from 2014 to 2019 were analyzed and divided into two groups based on whether they had SE. Their clinical characteristics during the neuro-ICU stay were assessed and compared. The neurological and seizure outcomes were evaluated every 3 months.

RESULTS: Of 83 patients with anti-NMDAR encephalitis, 24 required intensive care. In the SE group, 38.5% (5 of 13) of patients developed refractory SE (RSE), and 21.3% (3 of 13) of patients developed super RSE. More patients in the SE group presented with seizures as the initial symptoms (53.8% vs. 9.1%, p = 0.033) and had a strong positive NMDAR antibody titer in the cerebrospinal fluid (76.9% vs. 27.3%, p = 0.043). More patients in the non-SE group had a good neurological outcome (modified Rankin Scale (mRS) score < 2) at 3 months after disease onset (60.0% vs. 15.4%, p = 0.039), but 83.3% of patients with SE had a mRS score < 2 at 9 months after disease onset, which was similar to the rate in the non-SE group. A total of 41.7% of patients with SE had their last seizure within 1 month from disease onset, which was significantly lower than the rate in the non-SE group (90%), but all the patients with SE became seizure free after the acute phase of disease.

CONCLUSIONS: Patients with critical anti-NMDAR encephalitis who present with SE have a high rate of RSE/super RSE and recover more slowly than patients without SE, but most of them will eventually achieve good long-term neurological outcomes and live seizure free after the acute phase.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Wang X, Wan J, Wei Z, et al. Status Epilepticus in Patients with Anti-NMDAR Encephalitis Requiring Intensive Care: A Follow-Up Study. Neurocrit Care. 2021. PMID: 34286465. doi:10.1007/s12028-021-01283-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。